Cover Image
市場調查報告書

Dompe Farmaceutici S.p.A.- 產品平台檢討

Dompe Farmaceutici S.p.A. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 298926
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Dompe Farmaceutici S.p.A.- 產品平台檢討 Dompe Farmaceutici S.p.A. - Product Pipeline Review - 2015
出版日期: 2015年05月13日 內容資訊: 英文 32 Pages
簡介

Dompe Farmaceutici S.p.A.是總公司設立於義大利的生物製藥企業,致力於肺動脈高血壓,神經營養性角膜炎,色素性視網膜炎等罕見疾病治療藥的研究開發及製造。同時也提供咳嗽,慢性阻塞性肺病,支氣管氣喘,鼻炎等呼吸系統疾病的治療藥及OTC藥。

本報告提供Dompe Farmaceutici S.p.A.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Dompe Farmaceutici S.p.A.的基本資料

  • Dompe Farmaceutici S.p.A.概要
  • 主要資訊
  • 企業資料

Dompe Farmaceutici S.p.A.:R&D概要

  • 主要的治療範圍

Dompe Farmaceutici S.p.A.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Dompe Farmaceutici S.p.A.:開發中產品概況

  • 後期階段產品開發中產品
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Dompe Farmaceutici S.p.A.:藥物簡介

  • reparixin
  • ladarixin
  • Recombinant Human Nerve Growth Factor
  • DF-2593A
  • Small Molecules to Antagonize CXCR1/2 for Bladder and Prostate Cancer

Dompe Farmaceutici S.p.A.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Dompe Farmaceutici S.p.A.:最近的開發平台資訊

Dompe Farmaceutici S.p.A.:暫停開發中的計劃

Dompe Farmaceutici S.p.A.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07077CDB

Summary

Global Markets Direct's, 'Dompe Farmaceutici S.p.A. - Product Pipeline Review - 2015', provides an overview of the Dompe Farmaceutici S.p.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Dompe Farmaceutici S.p.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Dompe Farmaceutici S.p.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Dompe Farmaceutici S.p.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Dompe Farmaceutici S.p.A.'s pipeline products

Reasons to buy

  • Evaluate Dompe Farmaceutici S.p.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Dompe Farmaceutici S.p.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Dompe Farmaceutici S.p.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Dompe Farmaceutici S.p.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dompe Farmaceutici S.p.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Dompe Farmaceutici S.p.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Dompe Farmaceutici S.p.A. Snapshot
    • Dompe Farmaceutici S.p.A. Overview
    • Key Information
    • Key Facts
  • Dompe Farmaceutici S.p.A. - Research and Development Overview
    • Key Therapeutic Areas
  • Dompe Farmaceutici S.p.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Dompe Farmaceutici S.p.A. - Pipeline Products Glance
    • Dompe Farmaceutici S.p.A. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Dompe Farmaceutici S.p.A. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Dompe Farmaceutici S.p.A. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Dompe Farmaceutici S.p.A. - Drug Profiles
    • reparixin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ladarixin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Human Nerve Growth Factor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DF-2593A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize CXCR1/2 for Bladder and Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Dompe Farmaceutici S.p.A. - Pipeline Analysis
    • Dompe Farmaceutici S.p.A. - Pipeline Products by Target
    • Dompe Farmaceutici S.p.A. - Pipeline Products by Route of Administration
    • Dompe Farmaceutici S.p.A. - Pipeline Products by Molecule Type
    • Dompe Farmaceutici S.p.A. - Pipeline Products by Mechanism of Action
  • Dompe Farmaceutici S.p.A. - Recent Pipeline Updates
  • Dompe Farmaceutici S.p.A. - Dormant Projects
  • Dompe Farmaceutici S.p.A. - Locations And Subsidiaries
    • Head Office
  • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Dompe Farmaceutici S.p.A., Key Information
  • Dompe Farmaceutici S.p.A., Key Facts
  • Dompe Farmaceutici S.p.A. - Pipeline by Indication, 2015
  • Dompe Farmaceutici S.p.A. - Pipeline by Stage of Development, 2015
  • Dompe Farmaceutici S.p.A. - Monotherapy Products in Pipeline, 2015
  • Dompe Farmaceutici S.p.A. - Out-Licensed Products in Pipeline, 2015
  • Dompe Farmaceutici S.p.A. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Dompe Farmaceutici S.p.A. - Phase III, 2015
  • Dompe Farmaceutici S.p.A. - Phase II, 2015
  • Dompe Farmaceutici S.p.A. - Phase I, 2015
  • Dompe Farmaceutici S.p.A. - Preclinical, 2015
  • Dompe Farmaceutici S.p.A. - Pipeline by Target, 2015
  • Dompe Farmaceutici S.p.A. - Pipeline by Route of Administration, 2015
  • Dompe Farmaceutici S.p.A. - Pipeline by Molecule Type, 2015
  • Dompe Farmaceutici S.p.A. - Pipeline Products by Mechanism of Action, 2015
  • Dompe Farmaceutici S.p.A. - Recent Pipeline Updates, 2015
  • Dompe Farmaceutici S.p.A. - Dormant Developmental Projects,2015
  • Dompe Farmaceutici S.p.A., Other Locations
  • Dompe Farmaceutici S.p.A., Subsidiaries

List of Figures

  • Dompe Farmaceutici S.p.A. - Pipeline by Top 10 Indication, 2015
  • Dompe Farmaceutici S.p.A. - Pipeline by Stage of Development, 2015
  • Dompe Farmaceutici S.p.A. - Monotherapy Products in Pipeline, 2015
  • Dompe Farmaceutici S.p.A. - Pipeline by Top 10 Target, 2015
  • Dompe Farmaceutici S.p.A. - Pipeline by Top 10 Route of Administration, 2015
  • Dompe Farmaceutici S.p.A. - Pipeline by Top 10 Molecule Type, 2015
  • Dompe Farmaceutici S.p.A. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top